Heterosubtypic Antibody Response Elicited with Seasonal Influenza Vaccine Correlates Partial Protection against Highly Pathogenic H5N1 Virus by Ding, Heng et al.
Heterosubtypic Antibody Response Elicited with
Seasonal Influenza Vaccine Correlates Partial Protection
against Highly Pathogenic H5N1 Virus
Heng Ding
1., Cheguo Tsai
1., Fan Zhou
1, Philippe Buchy
2, Vincent Deubel
2, Paul Zhou
1*
1Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences,
Shanghai, China, 2Institut Pasteur in Cambodia, Phnom Penh, Cambodia
Abstract
Background: The spread of highly pathogenic avian influenza (HPAI) H5N1 virus in human remains a global health concern.
Heterosubtypic antibody response between seasonal influenza vaccine and potential pandemic influenza virus has
important implications for public health. Previous studies by Corti et al. and by Gioia et al. demonstrate that heterosubtypic
neutralizing antibodies against the highly pathogenic H5N1 virus can be elicited with a seasonal influenza vaccine in
humans. However, whether such response offers immune protection against highly pathogenic H5N1 virus remained to be
determined.
Methodology/Principal Findings: In this study, using a sensitive influenza HA (hemagglutinin) and NA (neuraminidase)
pseudotype-based neutralization (PN) assay we first confirmed that low levels of heterosubtypic neutralizing antibody
response against H5N1 virus were indeed elicited with seasonal influenza vaccine in humans. We then immunized mice with
the seasonal influenza vaccine and challenged them with lethal doses of highly pathogenic H5N1 virus. As controls, we
immunized mice with homosubtypic H5N1 virus like particles (VLP) or PBS and challenged them with the same H5N1 virus.
Here we show that low levels of heterosubtypic neutralizing antibody response were elicited with seasonal influenza
vaccine in mice, which were significantly higher than those in PBS control. Among them 2 out of 27 whose immune sera
exhibited similar levels of neutralizing antibody response as VLP controls actually survived from highly pathogenic H5N1
virus challenge.
Conclusions/Significance: Therefore, we conclude that low levels of heterosubtypic neutralizing antibody response are
indeed elicited with seasonal influenza vaccine in humans and mice and at certain levels such response offers immune
protection against severity of H5N1 virus infection.
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Introduction
Influenza A viruses are segmented, negative-strand RNA viruses
in the family Orthomyxoviridae. On the basis of the antigenicity of
HA and NA glycoproteins, influenza A viruses are classified into
16 HA subtypes (H1–H16) and 9 NA subtypes (N1–N9). To date,
human influenza A virus subtypes have been limited to H1, H2
and H3 and to N1 and N2 [1]. Other subtypes, such as H5, H7,
H9 and N7, that have been isolated from avian hosts, cause
sporadic human outbreaks [2,3].
Neutralizing antibody responses play an important role in
prevention and clearance of influenza A virus infection. However,
neutralizing antibodies are completely protective against second-
ary infections only with closely related influenza A strains, but
ineffective against viruses with major antigenic divergence.
Because of this, current seasonal influenza vaccines, which consists
of human influenza A viruses of H1N1 and H3N2 subtypes and an
influenza B virus, are prepared annually on the basis of WHO
forecasts on the most probable influenza A and B virus strains
thought to be circulating in the next seasonal outbreak [4,5]. From
the public health point of view, it is important to determine if
antibody responses elicited with seasonal influenza vaccines can
cross neutralize other HA subtypes that caused outbreaks in
humans.
Previously, Gioia et al reported that influenza vaccination
boosted heterosubtypic immunity against H5N1 viruses and the
immunity involved both cytotoxic T cell and antibody responses.
A rise of neutralization titer against H5N1 viruses after the
seasonal influenza vaccination was only detected by microneu-
tralization (MN) assay, but not hemagglutinin inhibition (HI) assay
[6]. However, in a small pilot study using similar immunogens and
immunization protocol for the same influenza season, Tang et al
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from seasonal influenza vaccine in human measured by both MN
and HI assays [7]. More recently, Corti et al. investigated the
human heterosubtypic antibody response following seasonal
influenza vaccination and reported that serum IgG antibodies in
some vaccinated individuals cross-react with H5 HA. Further-
more, by immortalizing memory B cells from those individuals, a
panel of 20 heterosubtypic neutralizing monoclonal antibodies
that bound and neutralized viruses belonging to H1, H2, H5, H6
and H9 subtypes were isolated [8]. Thus, heterosubtypic
neutralizing antibodies against highly pathogenic H5N1 virus
and other HA subtypes could indeed be elicited with seasonal
influenza vaccine in humans. However, it remains to be
determined whether such heterosubtypic neutralizing antibody
responses offer immune protection and if so, what neutralizing
antibody titers are required for immune protection.
Previously, we developed a sensitive influenza HA and NA
pseudotype-based neutralization (PN) assay [9]. We showed that
although there is an excellent correlation in neutralizing antibody
titers measured by the HI, MN and PN assays, in serum samples
with low neutralizing antibody activity the PN assay exhibits
greater sensitivity than the HI and MN assays.
Thus, in this study, using the sensitive PN assay we first tested if
antibody responses elicited with seasonal influenza vaccines in
healthy individuals can cross-neutralize H5N1 viruses. We
hypothesized that heterosubtypic neutralizing antibody response
against H5N1 viruses elicited with seasonal influenza vaccines may
be too low to be consistently detected by conventional HI and MN
assays, but can be readily detected by the sensitive PN assay. To
accomplish this, 12 healthy volunteers were recruited and
vaccinated with 2008–2009 seasonal influenza vaccines. Neutral-
izing antibody responses in the pre- and post-immune serum
samples were evaluated by two modified PN assays - PN entry
assay and PN release/entry assay - against a panel of HA and NA
pseudotypes derived from H1N1, H3N2 and H5N1 viruses. We
then immunized mice with the seasonal influenza vaccine,
homosubtypic H5N1 VLP or PBS control and challenged them
with lethal doses of highly pathogenic H5N1 virus. Neutralizing
antibody responses against H1N1, H3N2 and H5N1 viruses in
pre- and post-immune sera were evaluated using PN entry assay.
Here we show that low levels of heterosubtypic neutralizing
antibody response were indeed elicited with seasonal influenza
vaccine in humans and in mice. Among them 2 out of 27 mice
whose immune sera exhibited similar levels of neutralizing
antibody response as VLP controls survived from highly
pathogenic H5N1 virus challenge. Therefore, we conclude that
low levels of heterosubtypic neutralizing antibody response can
indeed be elicited with seasonal influenza vaccine in humans and
mice and such response, when reached at certain levels, offers
immune protection against severity of H5N1 virus infection.
Ethical Statement
Our human study was approved by the research and ethics
committee in the Institut Pasteur of Shanghai. All human
participants gave written consent. Our animal study was approved
by animal research committee in Pasteur Institute in Cambodia
and was carried out according to international guideline of animal
research.
Materials and Methods
Study Population
Twelve healthy young adult volunteers who were going to
receiving 2008–2009 seasonal influenza vaccine gave written
consent for sera to be taken prior to and after the vaccination at
the Institut Pasteur of Shanghai, Chinese Academy of Sciences.
The study was approved by the Institution Ethic Committee. The
vaccine formulation was Vaxigrip, an inactivated split influenza
vaccine (Sanofi Pasteur, Lyon, France). The antigen composition
and strains were A/Brisbane/59/2007 (H1N1), A/Brisbane/10/
2007 (H3N2) and B/Florida/4/2006 like. Each 0.5 ml vaccine
dose contains 15 mg HA of each strain in PBS and excipients.
Vaccine was administered intramuscularly. Blood samples were
drawn 1 or 2 months before and 10 days after the vaccination.
After clotting at room temperature for 6 hours and then at 4uC
overnight, serum samples were collected, heat-inactivated at 56uC
for 30 minutes and stored in aliquot at 280uC.
Cell lines
The packaging cell line 293T [9] was maintained in complete
DMEM medium [i.e. high glucose DMEM supplemented with
10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, penicillin
(100 U/ml), and streptomycin (100 mg/ml); Invitrogen Life
Technologies] containing 0.5 mg/ml of G418. Madin-Darby
canine kidney (MDCK) cell lines [9] were maintained in complete
DMEM medium.
Viruses
HPAI H5N1 viruses A/Shenzhen/406H/06 and A/Cambo-
dia/P0322095/05 were originally isolated from H5N1 infected
human patients at the Donghu Hospital in Shenzhen, China [10]
and the Pasteur Institute of Cambodia [11], respectively. Human
influenza A H1N1 virus A/WSN/33 was provided by Dr. Toyoda
in the Institute Pasteur of Shanghai. Viruses were propagated in
MDCK cells. Virus stocks were collected and stored in aliquot at
280uC. The fifty percentage tissue culture infection dose (TCID50)
of virus stocks was determined by infecting MDCK cells with serial
10-fold dilution of virus and calculated by the method of Reed and
Muench [12]. To determine 50% mouse lethal dose (MLD50)o f
the HPAI H5N1 virus A/Shenzhen/406H/06, groups of 5 mice
were inoculated i. n. with serial 10-fold dilution of virus. After the
inoculation, mice were monitored daily for 14 days. Any mouse
that lost more than 25% of its initial body weight was
euthanatized. MLD50 was calculated by the method of Reed
and Muench [12]. All research with HPAI H5N1 viruses was
conducted in bio-safety level 3 (BSL-3) facilities at the Pasteur
Institute of Cambodia under the guidance of the Institutional
Animal Care and Use Committee.
HA and NA pseudotype-based neutralization (PN) assay
HA and NA pseudotype panel used in this study was generated
as described previously [9]. The PN assay was carried out also as
described before [9] with some modifications.
1. PN entry assay
To test effect of pre- and post-immune sera on the entry of HA
and NA pseudotypes, MDCK cells (2610
4 cells per well) were
seeded onto 24 well culture plate in complete DMEM overnight.
Serially 4-fold diluted human sera or serially 2-fold diluted mouse
sera (starting at 1:10 dilution) were then incubated with various
pseudotypes equivalent to 100,000–500,000 relative luciferase
activity (RLA) at the final volume of 50 mla t3 7 uC for 1 hour. The
mixture was added onto MDCK cells and incubated for 2 days.
RLA in the cell lysates was measured as described before [9]. The
% inhibition was calculated by (RLA in pseudotypes and medium
control – RLA in pseudotypes and immune serum in a given
dilution)/RLA in pseudotypes and medium control. IC50 and
Heterosubtypic Immunity against H5N1 Virus
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that result in 50% and 90% reduction of luciferase activity,
respectively.
2. PN release/entry assay
To test the effect of pre- and post-immune sera on HA and NA
pseudotype release, 4610
5 293 T packaging cells were co-
transfected with 1.4 mg transfer vector pHR’CMV-Luc [13],
1.4 mg packaging vector pCMVDR8.2 [14], 0.2 mg CMV/R-HA
and 0.05 mg CMV/R-NA or with 1.4 mg pHR’CMV-Luc, 1.4 mg
pCMVDR8.2 and 0.5 mg CMVR-VSV-G control in 12 well tissue
culture plate as described before [9]. After overnight incubation,
cells were cultured in complete DMEM supplemented with
100 mM sodium butyrate for 8 hrs. Cells were then cultured in
1 ml of complete DMEM overnight in the presence of serially 4-
fold diluted sera (starting at 1:10 dilution). Culture supernatants
were collected and used to transduce MDCK cells overnight as
described before [9]. Forty eight hours after the transduction,
transduced cells were harvested and the luciferase activity was
measured as described above.
Micro-neutralization (MN) assay
MDCK cells (1.5610
4 cells per well) were seeded onto 48 well
culture plate in complete DMEM overnight. To test neutralization
activity of human pre- and post-immune serum samples, serially 4-
fold diluted sera (starting at 1:10 dilution) were incubated with 100
TCID50 wild type viruses A/Shenzhen/406H/06, A/Cambodia/
P0322095/05 and A/WSN/33 at the final volume of 50 mla t
37uC for 1 hour. After the incubation, the mixture was added onto
MDCK cells. The cytopathic effect (CPE) was scored at 4 days
after infection as described before [9]. The assay was performed in
triplicate.
Animals
All animal protocols were approved by the Institutional Animal
Care and Use Committee at the Institut Pasteur in Cambodia
(Permit number VD100820). Female BALB/c mice (Mus
musculus) at the age of 6 to 8 weeks were purchased from Charles
River Laboratories (L’Arbresle, France) and housed in micro-
isolator cages ventilated under negative pressure with HEPA-
filtered air and a 12/12-hour light/dark cycle.
Production and characterization of VLP
The production and characterization of influenza HA and NA
VLP were the same as described before [9]. Briefly, 4.5610
6 293T
cells were co-transfected with 14 mg pCMVDR8.2, 2 mg CMV/R-
H5HA (A/Shenzhen/406H/06) and 0.5 mg CMV/R-M2 epi-
tope-tagged N1NA (A/Thailand/1(KAN-1)/04) using a calcium
phosphate precipitation method. After overnight incubation, cells
were cultured in 10 ml of complete DMEM supplemented with
100 mM sodium butyrate for 8 hrs. Cells were then cultured in
10 ml of complete DMEM. The VLP-containing supernatants
were harvested in 16 to 20 hrs, loaded onto 20% sucrose cushion
and ultra-centrifuged at 20,000 rpm for 2.5 hours at 4uCi na
Beckman SW28 rotor (Beckman Coulter, Fullerton, CA). The
pellets were resuspended in PBS and stored in aliquot at 280uC.
To characterize VLP, resuspended pellets were fractionated
through a 25–65% sucrose density gradient at 25,000 rpm for
16 hours at 4uC in a Beckman SW41 swing rotor (Beckman
Coulter, Fullerton, CA). Twelve fractions (0.96 ml each) were
collected from the top to the bottom of the gradient, TCA
precipitated, separated by 12% SDS-PAGE and transferred
onto PDVF membranes. Blots were blocked in a solution of
Tris-buffered saline containing 5% nonfat dry milk and 0.1%
Tween 20 and subsequently probed with a monoclonal antibody
(clone 183-H12) specific for HIV-1 gag p24 (provided by the AIDS
Reagents and Depositary program, NIAID, NIH), with a
monoclonal antibody (Catalog# F3165, Sigma) specific for M2
epitope and with immune sera elicited with DNA plasmids
expressing H5HA A/Shenzhen/406H/06) (see below). Antigens
were visualized with an AP-conjugated anti-mouse IgG antibody
according to manufacturer’s instruction (Promega).
Immunization and challenge
Two immunization and challenge experiments were performed.
In the first experiment, female BALB/c mice at the age of 6 to 8
weeks were randomly divided into 3 groups (5 mice per group).
Mice in group one were injected intramuscularly (i.m.) with total
200 ml PBS (pH 7.4) in both prime and boost. Mice in group two
were injected i.m. with 0.5 mg (based on HA content) HA and NA
VLP in total 200 ml PBS for both prime and boost. Mice in group
three were injected i.m. with the same 2008–2009 seasonal
influenza vaccine as used in humans (see above). Each 200 ml
vaccine dose contains total 1 mg HA in PBS and excipients. The
prime and the boost were carried 21 days apart. Seven days before
the prime and 7 days after the boost serum samples were collected,
heat-inactivated at 56uC and stored in aliquot at 280uC. Two
weeks after the boost, mice in each group were challenged i.n. with
10 MLD50 of H5N1 virus (A/Shenzhen/406H/06, subclade 2.3.4)
in a volume of 50 ml. Mice were monitored and recorded daily for
14 days post challenge. When mice lose 25% or more of their
initial body weight, they were sacrificed and counted as dead mice.
Virus challenge studies were conducted in BSL-3 facility at the
Institut Pasteur in Cambodia in accordance with the Depart-
ment of Agriculture guidelines for the Care and Use of Labo-
ratory Animals, the Animal Welfare Act and Department of Agri-
culture Biosafety guidelines in Microbiological and Biomedical
Laboratory.
Since in the first immunization and challenge experiment all 5
PBS control mice died, all 5 VLP control mice survived and one of
5 seasonal influenza vaccinated mice whose immune serum
reached similar level as VLP controls actually survived from lethal
H5N1 challenge, we carried out the second immunization and
challenge experiment. In the second experiment 2 mice were
injected with PBS, 2 mice with VLP and 22 mice with seasonal
influenza vaccine followed by the same H5N1 challenge.
Statistical Analysis
Each individual animal immune response was counted as an
individual value for statistical analysis. The neutralizing activity
was first analyzed by the Kolmogorov-Smirnov and Shapiro-Wilk
normality tests for normality and then the significance was
calculated by Student’s t test. The log-rank test was used to
compare the survival curves.
Results
Neutralizing antibody titers in pre- and post-immune
sera measured by PN entry and MN assays
Tables 1 and 2 show neutralization titers (IC50) measured by
PN entry assay against a panel of H1N1, H3N2 and H5N1
pseudotypes as well as VSV-G controls in pre- and post-human
sera of 12 donors vaccinated with 2008–2009 trivalent seasonal flu
vaccine. All H1N1 and H5N1 pseudotypes express a common
N1NA. Six H5N1 pseudotypes express H5HA from clade 0 (A/
Hong Kong/156/97), clade 1 (A/Vietnam/1203/04 and A/
Cambodia/P0322095/05), subclade 2.1 (A/Indonesia/5/05),
Heterosubtypic Immunity against H5N1 Virus
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chicken/Hong Kong/SF189/01). Except for the clade 3, all other
5 H5HA were derived from human H5N1 isolates.
Before 2008–2009 seasonal influenza vaccination, sera from 7, 5
or 3 of 12 donors exhibited low, but measurable neutralization
titers (IC50 ranging from 1:10 to 1:320) against H1N1 A/WSN/
33 and A/Brisbane/59/2007 or H3N2 A/Brisbane/10/2007
pseudotypes (Table 1), but none of them against H5N1
pseudotypes derived from A/Hong Kong/156/97 (clade 0), A/
Cambodia/P0322095/05 (clade 1), A/Indonesia/5/05 (subclade
2.1) and A/silky chicken/Hong Kong/SF189/01 (clade 3) as well
as against pseudotype expressing VSV-G control (Table 2). Sera
from 1 (Subject #12) of 12 donors exhibited very low
neutralization titers (IC50 from 1:10 to 1:40) against H5N1
pseudotypes derived from A/Vietnam/1203/04 (clade 1) and A/
Shenzhen/406H/06 (subclade 2.3) (Table 2). At this moment, it is
not clear whether pre-existing very low anti-H5N1 neutralizing
antibody response detected in this individual is due to previous
exposure to H5N1 or other influenza A viruses.
After 2008–2009 seasonal influenza vaccination, sera from all
12 donors exhibited much higher neutralization titers (IC50
ranging from 1:640 to .2560 and IC90 ranging from 1:40 to
1:2,560) against H1N1 A/WSN/33 and A/Brisbane/59/2007 or
H3N2 A/Brisbane/10/2007 pseudotypes, but none of them
against pseudotype expressing VSV-G controls. Interestingly,
post-immune sera from 11 of 12 donors also exhibited neutral-
ization activity against at least one of H5N1 pseudotypes. Among
them post-immune sera from 3 donors (Subject #1, #2 and #4)
have low neutralization titers (IC50 ranging from 1:10 to 1:160)
against all 6 H5N1 pseudotypes. Compared to the pre-immune
sera, neutralization titers in post-immune sera increased at least 4
folds or higher (Tables 1 and 2).
For the comparison, neutralization titers were also measured by
a standard MN assay against two representative H5N1 strains (A/
Cambodia/P0322095/05 and A/Shenzhen/406H/06) and H1N1
strain (A/WSN/33). Before 2008–2009 seasonal flu vaccination,
sera from all 12 donors exhibited no detectable levels of
neutralization titers against all three strains; while after 2008–
2009 seasonal flu vaccination, sera from 8 of 12 donors exhibited
neutralization activity at the serum dilution from 1:10 to 1:160
against H1N1 strain; but still none of them have measurable
neutralization activity against 2 H5N1 strains (Table 3), even
though neutralization activity against H5N1 pseudotypes express-
ing H5HA isolated from the same two H5N1 strains was detected
by PN entry assay (Table 2). Thus, taken together the data clearly
show that in most human individuals 2008–2009 seasonal
Table 1. Neutralizing antibody titers against H1N1 and H3N2 in pre- and post-immune sera measured by PN (entry) assay.
H1N1 Vaccine antigen strain
A/WSN/33 H1N1 A/Brisbane/59/2007 H3N2 A/Brisbane/10/2007 VSV
Human
projects IC50 IC90 IC50 IC90 IC50 IC90 IC50
Pre- 1 ,1:10* ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
immune 2 1:10–1:40 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
sera 3 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
4 1:40–1:160 1:10–1:40 1:10–1:40 ,1:10 1:10–1:40 ,1:10 ,1:10
5 1:160–1:640 1:10–1:40 1:40 ,1:10 ,1:10 ,1:10 ,1:10
6 1:160–1:640 1:40 1:10 ,1:10 1:10 ,1:10 ,1:10
7 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
8 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
9 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
10 1:160–1:640 1:40 1:10 ,1:10 1:10 ,1:10 ,1:10
11 1:40–1:160 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
12 1:160–1:640 1:40 1:40 ,1:10 ,1:10 ,1:10 ,1:10
Post- 1 .1:2560** 1:640–1:2560 .1:2560 1:640–1:2560 1:640–1:2560 1:40 ,1:10
Immune 2 1:640 1:40 1:640–1:2560 1:40–1:160 1:160–1:640 1:10–1:40 ,1:10
sera 3 1:640 1:40–1:160 1:640–1:2560 1:40–1:160 1:160–1:640 1:10–1:40 ,1:10
4 .1:2560 1:40–1:160 .1:2560 1:160–1:640 1:160–1:640 1:40 ,1:10
5 1:640–1:2560 1:160–1:640 1:640–1:2560 1:160–1:640 1:40–1:160 1:10 ,1:10
6 1:640–1:2560 1:40–1:160 1:640–1:2560 1:160–1:640 1:40–1:160 1:10 ,1:10
7 .1:2560 1:640–1:2560 .1:2560 1:640–1:2560 1:160–1:640 1:10–1:40 ,1:10
8 1:640 1:40 1:640–1:2560 1:40–1:160 1:40–1:160 ,1:10 ,1:10
9 1:640–1:2560 1:160–1:640 .1:2560 1:160–1:640 1:40–1:160 1:10–1:40 ,1:10
10 1:640–1:2560 1:160–1:640 .1:2560 1:160–1:640 1:40–1:160 1:10 ,1:10
11 .1:2560 1:640–1:2560 .1:2560 1:640–1:2560 1:160–1:640 1:40 ,1:10
12 1:640–1:2560 1:160–1:640 1:640–1:2560 1:160–1:640 1:40–1:160 1:10–1:40 ,1:10
*,1:10: not detected.
**.1:2560: the Ab titers greater than the highest antibody dilutions.
doi:10.1371/journal.pone.0017821.t001
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heterosubtypic neutralizing antibody responses against H5N1
viruses. However, such heterosubtypic neutralizing antibody
responses can be only detected by sensitive PN entry assay, but
not by MN assay.
Effect of pre- and post-immune sera on release of HA and
NA pseudotypes
We next performed PN release/entry assay to determine the
effect of pre- and post-human immune sera on pseudotype release.
To accomplish this, 293T cells were first co-transfected with
pHR’CMV-Luc, pCMVDR8.2, one of two CMV/R-H5HA (A/
Cambodia/P0322095/05 and A/Shenzhen/406H/06) and
CMVR-N1NA or with pHR’CMV-Luc, pCMVDR8.2, and
CMVR-VSV-G control as described before [9]. After the
overnight incubation, cells were thoroughly washed and cultured
in complete DMEM medium supplemented with sodium butyrate
for 8 hours. Cells were then washed again and incubated in the
fresh complete DMEM medium in the presence or absence of
serially 4-fold diluted human pre- and post-immune sera for
18 hours. The supernatants were harvested and used to transduce
MDCK cells. After the transduction, relative luciferase activity was
measured. Table 4 shows IC50 of sera of 12 donors before and
after 2008–2009 seasonal influenza vaccination on H5N1
pseudotype and pseudotype expressing VSV-G control measured
by PN release/entry assay.
Before 2008–2009 seasonal influenza vaccination, sera from 7 of
12 donors exhibited low, but measurable neutralization titers
(IC50 ranging from 1:40 to 1:640 serum dilution) against H5N1
pseudotype A/Cambodia/P0322095/05 and sera from 9 of 12
donors exhibited low, but measurable neutralization titers (IC50
ranging from 1:10 to 1:160 serum dilution) against H5N1
pseudotype A/Shenzhen/406H/06, while none of them exhibited
detectable levels of neutralization activity against VSV-G control.
After 2008–2009 seasonal influenza vaccination, sera from 11 of
12 donors exhibited at least 4 fold increased neutralization titers
against H5N1 pseudotypes A/Cambodia/P0322095/05 and A/
Shenzhen/406H/06. But still none of them exhibited detectable
levels of neutralization activity against VSV-G control. Sera from
remaining 1 donor (Subject #10) that did not exhibit increased
neutralization titers after 2008–2009 seasonal influenza vaccina-
tion actually had the highest neutralization titers in the pre-
immune serum samples. Thus, these data indicate that low, but
measurable levels of neutralization activity against H5N1 virus
Table 2. Neutralizing antibody titers against H5N1 in pre- and post-immune sera measured by PN (entry) assay.
H5N1
A/Hongkong/
156/97 clade 0
A/Vietnam/1203/
04 clade 1
A/Cambodia/
P0322095/05 clade 1
A/Indonesia/
5/05 clade 2.1
A/Shenzhen/
406H/06 clade
2.3.4
A/Silky Chicken/Hongkong/
SF189/01 clade 3
Human
projects IC50 IC50 IC50 IC50 IC50 IC50
Pre- 1 ,1:10* ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
immune 2 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
sera 3 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
4 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
5 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
6 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
7 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
8 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
9 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
11 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
12 ,1:10 1:10–1:40 ,1:10 ,1:10 1:10 ,1:10
Post- 1 1:40 1:160 1:640 1:640 1:160–1:640 1:10
immune 2 1:40–1:160 1:40 1:160 1:160 1:40 1:40
sera 3 1:10 ,1:10 ,1:10 1:40 1:10 ,1:10
4 1:160–1:640 1:160 1:40 1:160 1:160 1:10–1:40
5 ,1:10 1:160 1:40–1:160 1:10–1:40 ,1:10 1:160
6 1:40 1:160 ,1:10 1:160 ,1:10 1:40–1:160
7 1:160 1:10–1:40 1:160 1:40 ,1:10 1:10
8 1:40 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
9 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10 ,1:10
10 ,1:10 ,1:10 ,1:10 ,1:10 1:40 ,1:10
11 1:10–1:40 1:40 ,1:10 1:10 1:10 ,1:10
12 1:10–1:40 1:40–1:160 ,1:10 ,1:10 1:40 ,1:10
*,1:10: not detected.
doi:10.1371/journal.pone.0017821.t002
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after seasonal influenza vaccination, neutralization activity against
H5N1 virus release significantly increases.
Effect of anti-HA versus anti-NA antibodies in immune
sera on virus release and entry
To better understand the contribution of anti-HA versus anti-
NA antibodies in immune sera to virus release and to virus entry,
we generated two immune sera against HA and NA, respectively,
by immunizing female BALB/c mice with DNA plasmids
expressing H5HA and N1NA, respectively. We then measured
their neutralization activity by both PN entry and PN release/
entry assays. Figure 1a shows that immune sera elicited with DNA
plasmid expressing H5HA exhibited significant and similar
neutralization activity when measured by both PN release/entry
and PN entry assays. In contrast, immune sera elicited with DNA
plasmid expressing N1NA exhibited significant neutralization
activity when measured by PN release/entry assay; while
measured by PN entry assay its neutralization activity was very
limited (Figure 1b). Thus, these results indicate that anti-NA
antibodies in immune sera mainly block virus release and have
minimum effect on virus entry; whereas anti-HA antibodies in
immune sera block virus entry, but not virus release. Thus, we
conclude that the neutralization titers against H5N1 pseudotypes
measured by PN entry assay (Table 2) truly reflected hetero-
subtypic anti-H5HA neutralizing antibody response; whereas the
neutralization titers measured by PN release/entry assay (Table 4)
reflected combined activity of both anti-NA neutralizing antibody
response that blocks virus release and heterosubtypic anti-H5HA
antibody response that blocks virus entry.
Protection efficacy after the HPAI H5N1 challenge
Having demonstrated that low levels of heterosubtypic neutral-
izing antibody responseagainst HPAI H5N1are indeed elicited with
seasonalinfluenzavaccineinhumans,wenexttestedifsuchantibody
response can also be elicited in mice and if so whether such antibody
response offers any immune protection against lethal challenge of
HPAI H5N1 viruses. To test this, we carried out two immunization
and challenge experiments. In the first experiment female BALB/c
mice randomly divided into three groups (5 mice per group) were
injected i.m. twice with PBS, VLP expressing H5HA and N1NA or
the seasonal influenza vaccine, respectively, followed by the
challenge of 10 MLD50 HPAI H5N1 A/Shenzhen/406H/06
viruses. Dose 10 MLD50 was chosen to ensure 100% mortality
rates in PBS control. In the second experiment 2 mice were injected
i.m. twice with PBS, 2 mice with VLP and 22 mice with seasonal
influenza vaccine followed by the same H5N1 challenge. Because
both experiments showed similar trends of protection efficacy, we
combined data of both experiments for analyses.
Figure 2a and 2b shows the time course of body weight change
and the survival rate of each group during 14 days post challenge,
respectively. In PBS control group, severe sickness of mice became
Table 3. Neutralizing antibody titers in pre- and post-immune sera measured by MN assay.
H1N1 H5N1
Human subjects A/WSN/33 A/Cambodia/P0322095/05 A/Shenzhen/406H/06
Pre- 1 ,1:10* ,1:10 ,1:10
immune 2 ,1:10 ,1:10 ,1:10
sera 3 ,1:10 ,1:10 ,1:10
4 ,1:10 ,1:10 ,1:10
5 ,1:10 ,1:10 ,1:10
6 ,1:10 ,1:10 ,1:10
7 ,1:10 ,1:10 ,1:10
8 ,1:10 ,1:10 ,1:10
9 ,1:10 ,1:10 ,1:10
10 ,1:10 ,1:10 ,1:10
11 ,1:10 ,1:10 ,1:10
12 ,1:10 ,1:10 ,1:10
Post- 1 1:40 ,1:10 ,1:10
immune 2 ,1:10 ,1:10 ,1:10
sera 3 ,1:10 ,1:10 ,1:10
4 ,1:10 ,1:10 ,1:10
5 1:10 ,1:10 ,1:10
6 1:10 ,1:10 ,1:10
7 1:40 ,1:10 ,1:10
8 ,1:10 ,1:10 ,1:10
9 1:10 ,1:10 ,1:10
10 1:10 ,1:10 ,1:10
11 1:160 ,1:10 ,1:10
12 1:10 ,1:10 ,1:10
*,1:10: not detected.
doi:10.1371/journal.pone.0017821.t003
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on day 4 after the challenge and between day 5 and 8 all 7 mice
died. In VLP group, all 7 mice became mild sick on 7 to 9 days post
challenge and mildly lost their body weight. After 10 days, all mice
started gaining weight and survived. In seasonal influenza vaccine
group, all 27 mice became sick and started loss of weighton day4 or
6. Between day 7 and 9, 25 mice died. The remaining 2 mice (#2
and #25) regained their body weight on day 9 and survived.
Neutralizing antibody responses and their protection
outcome
To better understand the immune protection, we compared
neutralizing antibody titers in post-boost immune sera in individual
mice against H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/
2007 and H5N1 A/Shenzhen/406H/06 pseudotypes using the PN
entry assay. As expected, all mice received PBS did not have any
neutralizing antibody activity against all three pseudotypes
(Figure 3a, b and c). All mice primed and boosted with seasonal
influenza vaccine exhibited high neutralizing antibody titers against
H1N1 (Figure 3a) and H3N2 (Figure 3b), but relatively lower
neutralizing antibody titers against H5N1 with exception of serum
samples from mice #2a n d#25 (Figure 3c). Interestingly, the mice
#2a n d#25 were the only two seasonal influenza vaccinated mice
whosurvivedfromlethalchallengeofHPAIH5N1viruses(Figure2).
In contrast, all mice primed and boosted with VLP expressing
H5HA and N1NA exhibited decent neutralizing antibody titers
against H5N1 (Figure 3c), but none of them had measurable
neutralization titers against H1N1 and H3N2 (Figure 3a and 3b).
To further determine whether the levels of heterosubtypic
neutralizing antibody responses elicited with seasonal influenza
vaccine are statistically significant, we compared neutralization
activity of immune sera among the three groups. Figure 4 shows
neutralization activity at 1:20 dilution of immune sera of
individual mice among the three groups. Both Kolmogorov-
Smirnov and Shapiro-Wilk normality tests show the normal
distribution of neutralization activity among the three groups of
serum samples (Heng et al. data not shown). Clearly, while
significantly higher heterosubtypic neutralizing antibody responses
were elicited with seasonal influenza vaccine as compared to PBS
control (P=0.00484), such antibody responses were also signifi-
cantly lower than those elicited with homosubtypic H5N1 VLP
(P,0.001). That may explain why 25 out of 27 mice after
immunized with seasonal influenza vaccine still died after lethal
H5N1 challenge. Interestingly, 2 (#2 and #25) out of 27 mice
whose immune sera reached neutralization levels similar to H5N1
VLP controls survived from lethal H5N1 challenge. At 1:20
dilution, sera from mice #2 and #25 exhibited 57% and 55%
inhibition, respectively; while at the same dilution, immune sera
from mice primed and boosted with H5N1 VLP exhibited 50 to
72% inhibition.
Table 4. Neutralizing antibody titers in pre- and post-immune sera measured by PN (release/entry) assay.
H5N1
Human subjects VSV A/Cambodia/P0322095/05 A/Shenzhen/406H/06
Pre- 1 ,1:10* 1:40 1:40
immune 2 ,1:10 1:40–1:160 1:10
sera 3 ,1:10 1:40–1:160 1:40–1:160
4 ,1:10 1:40–1:160 1:10–1:40
5 ,1:10 ,1:10 1:10–1:40
6 ,1:10 ,1:10 1:40
7 ,1:10 1:40 ,1:10
8 ,1:10 ,1:10 ,1:10
9 ,1:10 1:10 1:10
10 ,1:10 1:160–1:640 1:160
11 ,1:10 ,1:10 ,1:10
12 ,1:10 ,1:10 1:10–1:40
Post- 1 ,1:10 .1:640** 1:640
immune 2 ,1:10 1:160–1:640 1:40
sera 3 ,1:10 .1:640 1:160–1:640
4 ,1:10 1:640 1:160–1:640
5 ,1:10 1:160–1:640 1:40–1:160
6 ,1:10 1:640 1:40–1:160
7 ,1:10 1:640 1:160–1:640
8 ,1:10 1:10 1:160
9 ,1:10 1:40–1:160 1:40
10 ,1:10 .1:640 1:160
11 ,1:10 1:10–1:40 1:40–1:160
12 ,1:10 1:40–1:160 1:40–1:160
*,1:10: not detected.
**.1:640: the Ab titers greater than the highest antibody dilutions.
doi:10.1371/journal.pone.0017821.t004
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17821Figure 1. Dissect the role of anti-HA and anti-NA antibodies in influenza HA and NA pseudotype release and entry. a) Titration of anti-
HA immune sera by PN entry and PN release/entry assays; b) Titration of anti-NA immune sera by PN entry and PN release/entry assays. Black close
square stands for anti-H5N1 neutralizing antibody response measured by PN release/entry assay; Red close square stands for anti-H5N1 neutralizing
antibody response measured by PN entry assay; Black open circle stands for anti-VSV-G neutralizing antibody response measured by PN release/entry
assay; Red open circle stands for anti-VSV-G neutralizing antibody response measured by PN entry assay.
doi:10.1371/journal.pone.0017821.g001
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Heterosubtypic neutralizing antibody response between the
annual seasonal influenza vaccine and other potential pandemic
influenza viruses such as HPAI H5N1 viruses has important
implications for public health pandemic influenza preparedness. In
the present study, we demonstrated that in most human
individuals 2008–2009 seasonal influenza vaccination elicited
low, but measurable, heterosubtypic neutralization activity against
various clades and subclades of H5HA and this heterosubtypic
Figure 2. Protection efficacy elicited with H5N1 VLP and seasonal influenza vaccine in mice challenged with 10 MLD50 of HPAI
H5N1 (A/Shenzhen/406H/06). a) Mean and standard deviation of percentage of original body weight in three groups as well as two individual mice
(#2 and #25) after challenged with HPAI H5N1 virus. Black line: PBS control group; red line: VLP group; blue line: seasonal influenza vaccine group;
purple line: mouse #2 vaccinated with seasonal influenza vaccine; green line: mouse #25 vaccinated with seasonal influenza vaccine. b) Survival rates
after challenged with HPAI H5N1 virus. Survival rate was calculated based on percent survival within each experimental group. Black line: PBS control
group; red line: VLP group; blue line: seasonal influenza vaccine group. The data shown here were the combined results of two individual experiments.
The survival curves between different groups were compared by the log-rank test. P values between PBS and seasonal influenza vaccination groups,
between PBS and VLP vaccination groups and between seasonal influenza and VLP vaccination groups were 0.0003, 0.0002 and ,0.0001, respectively.
doi:10.1371/journal.pone.0017821.g002
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not by MN assay. Thus, on one hand our results (Tables 1, 2 and
4) agree with what was reported by Gioia et al [6], Corti et al [8],
Garcia et al [15] and Kositanont et al [16] that indeed there is
heterosubtypic neutralizing antibody response between the
seasonal influenza vaccine with HPAI H5N1 viruses. On the
other hand, our results (Table 3) also agree with what was reported
by Tang et al [7] that the neutralization activity was not detected
by MN assay.
The PN assay is not only more sensitive than conventional MN
and HI assays, but also allows us to dissect whether the
neutralizing antibody responses act on virus release or virus entry
or both (see Materials and Methods for detail assay description). In
the present study, by measuring pre- and post-human immune
sera as well as mouse immune sera against N1NA or H5HA with
both PN entry and PN release/entry assays (Tables 1, 2 and 4 and
Figure 1) we were able to conclude that seasonal influenza
vaccination elicits both homosubtypic anti-N1NA and hetero-
subtypic anti-H5HA antibodies in human immune sera. The
former blocks virus release; whereas the latter blocks virus entry.
A number of studies in animals have shown that cross-protective
immunity against H5N1 can be elicited with seasonal influenza
vaccines or infection [17–25]. Although majority of such cross-
subtypic protection are thought to be mediated by T cells against
shared conserved epitopes in viral internal proteins such as NP and
M1 between seasonal influenza vaccine and H5N1 viruses [26–
31], several studies did show seasonal influenza vaccination elicited
B cell responses [17,19,23,24,25]. For example, one study showed
that priming animals with trivalent live attenuated seasonal
influenza vaccine indeed significantly increased anti-H5N1 B cell
responses [19]. Another studies using gene-targeted B cell (igH-
6
2/2)o rb2-microglobulin (b2m
2/2) deficient mice showed that
heterosubtypic immune protection against lethal challenge of
HPAI H5N1 viruses elicited with intranasal immunization of
inactivated influenza H3N2 vaccine plus LT (R192G) adjuvant
was mediated by B cells, but not by CD8
+ T cells [25]. Moreover,
antibody response induced by the influenza A virus N1NA affords
partial protection against H5N1 viruses in mice and such antibody
response was detected in humans with no history of H5N1
exposure [17,23]. Finally, parental immunization of CD1 mice
with trivalent seasonal influenza vaccine elicited heterosubtypic
H5-reactive antibodies that confer partial protection against
H5N1 influenza challenge [24].
Although these aforementioned studies strongly suggested that
antibody responses elicited with seasonal influenza vaccines confer
certain degree of protection against heterosubtypic H5N1
challenge, what neutralizing antibody titers were required for
such protection was not clear. In the present study, the sensitive
PN assay enables us to detect low levels of heterosubtypic
neutralizing antibody responses in mice elicited with seasonal
influenza vaccine (Figure 3c). Among them 2 mice whose immune
sera at 1:20 dilution exhibited higher than 50% heterosubtypic
neutralizing antibody activity actually survived from lethal
challenge of H5N1 virus; while all remaining 25 mice whose
heterosubtypic neutralizing antibody activity at 1:20 dilution was
lower than 50% inhibition died (Figures 2b and 4). Actually, the
Figure 4. Statistical analysis of neutralizing antibody activity of immune sera at 1:20 dilution among three groups. Horizontal bars
show the mean values of percentage inhibition in each of three groups. The data shown here were the combined results of two individual
experiments.
doi:10.1371/journal.pone.0017821.g004
Figure 3. Mean and standard deviation of percentages of inhibition by mouse immune sera against influenza H1N1 (a), H3N2 (b)
and H5N1 (c). PBS: sera from individual PBS control mouse group; VLP: immune sera from individual mice immunized with H5N1 VLP; Vaxigrip:
immune sera from individual mice immunized with seasonal influenza vaccine. The data shown here were the combined results of two individual
experiments.
doi:10.1371/journal.pone.0017821.g003
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detected in these two survived mice were similar to that detected
in H5N1 VLP vaccinated mice (Figure 3b). Taken together, these
results did indicate that when heterosubtypic neutralizing antibody
activity in immune sera at 1:20 dilution is equal to and higher than
50% inhibition, such levels of neutralizing antibody activity may
be indeed high enough to offer protection against severity of
diseases caused by lethal challenge of highly pathogenic H5N1
virus.
Finally, in the present study we also showed that in most human
cases immune sera elicited with seasonal influenza vaccination had
several fold higher heterosubtypic neutralizing antibody responses
against H5N1 than those found in two survived mice mentioned
above (see Table 2). Therefore, if the levels of heterosubtypic
neutralizing antibody activity that protect mice from lethal
challenge of H5N1 virus could be extrapolated in humans,
seasonal influenza vaccination may also offer immune protection
against severity of HPAI H5N1 infection in humans.
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